NCT07604545Withdrawn
A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema
Predictive Value of OCT Inflammatory Biomarkers in DME Using AI Analysis
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 18 May 2026
- Start date
- 30 May 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- AbbVie
- Diseases
- Diabetic eye disease
- NCT number
- NCT07604545
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of eyes with previous intravitreal or laser treatment for DME.
- History of eyes with previous intraocular or periocular corticosteroid for DME.
Other illness
- History eyes with other macular disease, causing visual reduction or disturbance.
Who the study is looking for
- Previously untreated Diabetic macular edema (DME) Participants.
- Baseline macular edema ≥350 microns confirmed on Spectralis Standard deviation (SD)-Optical coherence tomography (OCT) or equivalent.
- Baseline Best corrected visual acuity (BCVA) between 23 and 78 Early treatment diabetic retinopathy study (ETDRS) letters (between 20/32 and 20/230 Snellen).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.